BOSTON, Nov. 23, 2020 /PRNewswire/ -- CSA Medical,
Inc., today announced metered cryospray utilizing the
RejuvenAir® System for the treatment of Chronic
Bronchitis was featured in multiple presentations at the
21st World Congress of Bronchology and Interventional
Pulmonology in Shanghai.
In a session entitled "The Evolution of Cryotherapy in
Bronchoscopy", Scott Parrish, MD,
Appleton Wisconsin, reviewed the
science of cryobiology highlighting the clinically meaningful
differences in temperature and cooling power of various cryotherapy
methods. "Liquid Nitrogen, at -196°C, is uniquely able to
flash freeze cellular material while preserving the extracellular
structures, enabling regrowth of normalized epithelium," summarized
Dr. Parrish.
Dr. Robert Browning Jr., Medical
Director, Interventional Pulmonology at Walter Reed National
Military Medical Center, who co-chaired the session, presented the
technology development of Metered Cryospray (MCS) from benchtop
catheter design and dosing, to clinical application for the
treatment of Chronic Bronchitis. Unlike end-spray catheter delivery
systems, the RejuvenAir System incorporates a circumferential
cryospray catheter and unique energy control algorithm which
deliver distinct cryospray doses to differing airway
diameters.
The RejuvenAir System is designed to address the underlying
cause of Chronic Bronchitis, the damaged cilia and mucus-producing
goblet cells lining the airways and enable a rejuvenative healing
response. SPRAY-CB, the pivotal study of the RejuvenAir System
in patients with COPD with Chronic Bronchitis, is actively
enrolling at major medical centers across the United States.
About COPD with Chronic Bronchitis
Chronic Bronchitis is the largest disease subset of Chronic
Obstructive Pulmonary Disease (COPD). Bronchitis is inflammation of
the bronchial airways. A chronic bronchitis diagnosis is defined by
cough with productive sputum of three months duration for two
consecutive years. In addition to a chronic inflammation, cough and
increased production of mucus, chronic bronchitis may or may not
present with obstruction/partially blocked airways due to swelling
and excess mucus in the bronchi, or shortness of breath (dyspnea).
In the United States, there are an
estimated 16 million people with COPD, of which over 9 million have
a diagnosis of chronic bronchitis, a subset of COPD. Approximately
700,000 people are hospitalized for symptoms/exacerbations of
chronic bronchitis every year. In Europe, there are approximately 23 million
people with COPD and approximately 1.5 million hospitalizations per
year for COPD.
About CSA Medical
CSA Medical, Inc. develops and manufactures proprietary
interventional liquid nitrogen spray cryotherapy systems that
utilize software-driven dosimetry and specialty catheters that
enable delivery of cryogen spray inside the airways to flash freeze
and destroy damaged cells allowing for a rejuvenative pattern of
healing. The RejuvenAir System is approved in the EU and
under clinical investigation in the
United States. To learn more about our technology or
clinical trials, please visit www.rejuvenair.com or
www.clinicaltrials.gov [Identifiers: NCT03893370 and
NCT03892694].
RejuvenAir is a registered trademark of CSA Medical, Inc.
Media Contact: Wendelin Maners,
wmaners@csamedical.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/csa-medical-announces-metered-cryospray-with-the-rejuvenair-system-for-the-treatment-of-chronic-bronchitis-featured-at-the-21st-world-congress-of-bronchology-and-interventional-pulmonology-301178518.html
SOURCE CSA Medical